

Supplementary Materials: Neoadjuvant Chemoradiotherapy Versus Chemotherapy for Gastroesophageal Junction Adenocarcinoma; Which Is the Optimal Treatment Option?

Eric Zandirad, Hugo Teixeira Farinha, Beatriz Barberá–Carbonell, Sandrine Geinoz, Nicolas Demartines, Markus Schäfer and Styliani Mantziari

Table S1. Logistic regression analysis for complete pathologic response (TRG1).

	Unadjusted OR	95%CI	P-value
% Baseline weight loss	1.03	0.88–1.19	0.669
cT stage			
2	1		
3–4	0.34	0.06–2.62	0.236
cN stage			
0	1		
1	0.34	0.07–1.59	0.158
2–3	1.50	0.24–8.52	0.644
Differentiation grade			
G1	1		
G2	0.75	0.09–16.0	0.811
G3	0.22	0.02–5.39	0.259
Baseline SUVmax	0.98	0.88–1.07	0.796
Signet–ring histology	0.41	0.02–2.44	0.419
HER2+ status	1.50	0.16–14.2	0.707
NAT type			
RCT	1		
CT	0.518	0.07–2.20	0.423

As only cN status had $p < 0.2$ in univariate analysis (simple logistic regression), multivariate analysis was not performed.

Table S2. Cox regression analysis for Overall Survival (OS).

	Unadjusted OR	95%CI	P-value	Adjusted OR	95%CI	P-value
% Baseline weight loss	1.02	0.93–1.11	0.698			
cT stage						
2	1		0.652			
3	1.59	0.21–12.2				
cN stage						
0	1					
1	1.48	0.42–5.21	0.538			
2–3	0.54	0.05–5.23	0.597			
SUVmax	0.96	0.89–1.03	0.301			
Signet–ring histology	0.76	0.22–2.59	0.665			
HER2+ status	0.24	0.02–2.45	0.23			
NAT type						
RCT	1		0.269			
CT	0.50	0.14–1.71				
RCT dose						
41.4Gy	1					
45Gy	2.24	0.57–8.79	0.246			
50.4Gy	2.22	0.57–8.62	0.248			
pT status						
0	1			1		

1	3.08	0.31–30.3	0.334	1.08	0.29–29.4	0.358
2	5.89	0.66–52.9	0.113	1.36	0.41–31.17	0.232
3	3.13	0.40–24.3	0.276	0.73	0.25–17.01	0.494
4	6.15	0.37–102.2	0.205	1.86	0.32–126.8	0.221
cN status						
0	1			1		
1	2.10	0.68–6.52	0.197	2.21	0.68–7.19	0.189
2	2.71	0.92–7.94	0.069	4.00	1.22–13.17	0.022
3	0.97	0.12–7.92	0.981	1.32	0.13–13.10	0.811
pCR	0.274	0.03–2.07	0.210			
R1 resection	1.60	0.51–5.04	0.422			
Major Complications	2.57	1.09–6.06	0.031	1.15	1.21–8.12	0.018

Variables with $p < 0.2$ in univariate analysis were included in the multivariate model.

Table S3. Cox regression analysis of Disease-Free Survival (DFS).

	Unadjusted OR	95%CI	P-value	Adjusted OR	95%CI	P-value
cT status						
2	1		0.334			
3	2.01	0.49–8.35				
cN status						
0	1					
1	1.32	0.60–2.91	0.484			
2–3	1.46	0.53–4.04	0.465			
Differentiation grade						
1	1			1		
2	1.68	0.39–7.28	0.485	1.19	0.25–5.75	0.821
3	2.89	0.67–12.4	0.153	1.97	0.42–9.18	0.387
SUVmax	1.01	0.97–1.05	0.635			
Signet-ring cell histology	1.39	0.69–2.82	0.359			
HER2+ status	0.38	0.09–1.49	0.167			
NAT type						
RCT	1		0.753			
CT	0.903	0.47–1.71				
pT status						
0	1			1		
1	0.25	0.05–1.27	0.094	0.19	0.03–1.12	0.066
2	0.95	0.27–3.38	0.937	0.52	0.09–2.95	0.466
3	1.04	0.44–2.50	0.919	0.46	0.13–1.58	0.219
4	6.32	1.49–26.8	0.012	0.91	0.06–13.9	0.947
pN status						
0	1			1		
1	2.49	1.16–5.36	0.019	1.94	0.74–5.10	0.177
2	3.55	1.67–7.55	<0.001	3.32	1.32–8.35	0.011
3	4.61	1.94–10.9	<0.001	4.85	1.25–18.8	0.022
TRG1	1.09	0.46–2.57	0.848			
R1 resection	2.40	1.22–4.71	0.011	1.28	0.49–3.34	0.614
Major complica- tions	0.64	0.34–1.21	0.172	0.741	0.34–1.62	0.452

Variables with $p < 0.2$ in univariate analysis were included in the multivariate model.